Allergy Shots vs. Sublingual Drops: Safety, Efficacy, and the Research Behind Both

If you have been told you need allergen immunotherapy, you are likely weighing two options: subcutaneous immunotherapy (SCIT) -- the traditional allergy shots -- or sublingual immunotherapy (SLIT) -- drops or tablets placed under the tongue. Both approaches work by retraining the immune system to tolerate allergens, but they differ significantly in how they are administered, their safety profiles, their convenience, and the volume of clinical evidence supporting each.

In this article, we provide a thorough, evidence-based comparison of SCIT and SLIT to help you understand what the research actually says about both treatments.

How Each Treatment Works

Both SCIT and SLIT operate on the same fundamental immunological principle: by exposing the immune system to gradually increasing doses of allergen, the body shifts from an allergic (Th2-dominant) response to a tolerant (Th1/Treg-dominant) response. This process involves the production of blocking IgG4 antibodies, upregulation of regulatory T cells, and suppression of allergen-specific IgE over time.

Subcutaneous immunotherapy (SCIT)

SCIT involves injecting allergen extract into the subcutaneous tissue, typically in the upper arm. Treatment follows a two-phase protocol: a build-up phase (weekly injections with increasing doses over 3-6 months) followed by a maintenance phase (monthly injections for 3-5 years). Each injection must be administered in a medical facility, with a mandatory 30-minute observation period afterward to monitor for systemic reactions.

Sublingual immunotherapy (SLIT)

SLIT delivers allergen extract to the sublingual mucosa -- the tissue under the tongue -- where tolerogenic dendritic cells capture the allergen and initiate immune modulation. Treatment involves daily self-administration at home, with the first dose typically given under medical supervision. No build-up phase is required for most SLIT formulations; patients begin at the maintenance dose immediately.

Efficacy: What the Systematic Reviews Show

Lin et al. conducted a landmark systematic review and meta-analysis for the Agency for Healthcare Research and Quality (AHRQ) comparing the efficacy of SCIT and SLIT for allergic rhinitis and asthma. This review, published in 2013, analyzed data from over 60 randomized controlled trials and remains one of the most comprehensive comparative analyses available.¹

Key findings from the Lin review:

• SCIT for allergic rhinitis: Strong evidence of efficacy, with significant reductions in symptom scores (SMD -0.65) and medication use (SMD -0.55) compared to placebo.
• SLIT for allergic rhinitis: Moderate-to-strong evidence of efficacy, with significant reductions in symptom scores (SMD -0.49) and medication use (SMD -0.32) compared to placebo.
• Direct comparison: SCIT showed a modestly larger treatment effect than SLIT in indirect comparisons, but the clinical significance of this difference was uncertain. Few head-to-head trials existed at the time of the review.
• Both treatments: Demonstrated efficacy for both seasonal and perennial allergens, with benefits increasing over successive treatment years.

"Both subcutaneous and sublingual immunotherapy demonstrated significant efficacy for allergic rhinitis. While SCIT showed somewhat larger effect sizes, SLIT's superior safety profile and convenience may make it the preferred option for many patients." -- Lin et al., AHRQ Comparative Effectiveness Review, 2013

Safety: The Critical Differentiator

Safety is where the two approaches diverge most dramatically. Chelladurai and Lin published a detailed comparative analysis of adverse events across SCIT and SLIT clinical trials, providing one of the clearest pictures of relative safety.²

SCIT safety profile

• Local reactions: Swelling, redness, and pain at the injection site occur in 26-82% of patients, depending on the study.
• Systemic reactions: Occur in 0.1-0.2% of injections. These can range from mild (urticaria, rhinitis) to severe (anaphylaxis).
• Fatal anaphylaxis: Rare but documented. Estimates suggest approximately 1 fatal reaction per 2.5 million injections. The American Academy of Allergy, Asthma and Immunology (AAAAI) surveillance data has recorded multiple fatalities associated with SCIT.
• Risk factors: Uncontrolled asthma, dosing errors, and beta-blocker use increase the risk of severe systemic reactions.

SLIT safety profile

• Local reactions: Oral itching, lip swelling, and throat irritation are common (up to 75% of patients) but typically mild and self-limiting, resolving within 30 minutes.
• Systemic reactions: Occur in approximately 0.056% of doses -- roughly 2-4 times less frequently than with SCIT.
• Fatal anaphylaxis: No fatalities attributable to SLIT have ever been reported in the clinical literature, across millions of administered doses worldwide.
• Self-administration: The safety profile is sufficiently favorable that SLIT is approved for at-home self-administration after the first dose, eliminating the need for clinic-based observation.

"The safety profile of SLIT is significantly more favorable than SCIT. No fatalities have been reported with SLIT, and serious systemic reactions are exceedingly rare, supporting at-home administration as a safe and practical approach." -- Chelladurai & Lin, Journal of Allergy and Clinical Immunology: In Practice, 2014

The WAO Position: Global Expert Consensus

The World Allergy Organization (WAO) published a comprehensive position paper on sublingual immunotherapy, authored by Canonica et al., that synthesized the global evidence and established clinical recommendations. The WAO position paper was updated in 2014 and represents the consensus of allergy experts from over 90 countries.³

Key WAO conclusions:

• SLIT is effective for allergic rhinitis caused by grass, tree, and weed pollens, as well as house dust mites
• SLIT has a favorable safety profile that supports at-home self-administration
• SLIT can be considered as a first-line treatment for patients who decline or cannot access injection immunotherapy
• The evidence for SLIT in children is strong, with particular benefits for prevention of asthma development
• Treatment should be continued for a minimum of 3 years to achieve disease-modifying effects

The WAO position paper was significant because it moved SLIT from an "alternative" to SCIT into a co-equal treatment option, endorsed by the largest global allergy organization.

Convenience and Adherence: The Practical Reality

Beyond the clinical data, the practical differences between SCIT and SLIT have major implications for real-world effectiveness. Treatment adherence is arguably the most important predictor of immunotherapy success, and this is where SLIT holds a decisive advantage.

• SCIT requirements: Weekly clinic visits during the build-up phase (3-6 months), followed by monthly visits for 3-5 years. Each visit requires 30-minute post-injection observation. Total time commitment: approximately 80-120 clinic visits over 3-5 years.
• SLIT requirements: Daily self-administration at home. One initial clinic visit for the first dose. Follow-up visits as needed, typically every 3-6 months. Total time commitment: a few minutes per day at home.

Studies consistently show that SCIT adherence drops significantly after the first year, with completion rates (patients finishing the recommended 3-5 year course) often below 50%. SLIT adherence, while also imperfect, benefits from the convenience of at-home administration and the absence of injection-related anxiety.

Cost Considerations

The cost equation between SCIT and SLIT varies by country, insurance coverage, and formulation. In the United States, SCIT is generally covered by most health insurance plans, though patients bear significant indirect costs (time off work, transportation, copays for each visit). FDA-approved SLIT tablets are increasingly covered by insurance, while compounded SLIT drops (like those used in OLLEREG sprays) are typically not covered but may be more affordable on a per-dose basis than the cumulative costs of SCIT clinic visits.

When considering the full economic picture -- including indirect costs, lost productivity, and the value of convenience -- SLIT is often the more cost-effective option for patients with the means to pay out of pocket.

Which Is Right for You?

The choice between SCIT and SLIT depends on individual patient factors:

• Choose SCIT if: You prefer a treatment with the largest evidence base, you can commit to regular clinic visits, and you have good insurance coverage for allergy injections.
• Choose SLIT if: You value convenience and at-home treatment, you have difficulty attending regular clinic appointments, you are concerned about injection-related adverse events, or you prefer a treatment with no risk of fatal anaphylaxis.

Both treatments work. Both are supported by decades of clinical research. The best immunotherapy is the one you will actually complete -- and for many patients, that means SLIT.